Products & Pipeline
As of February 1, 2012, the chart below summarizes the status of our marketed products and compounds under development.
| * | ZEGERID is a non-promoted prescription product that continues to generate revenue. In addition, ZEGERID OTC® is promoted by MSD Consumer Products, Inc., a subsidiary of Merck & Co., Inc. GlaxoSmithKline and Norgine have rights to ZEGERID in certain territories outside the U.S. |
| Full Prescribing and Safety Information | |
| Full prescribing and safety information for GLUMETZA, including a Black Box warning, is available at www.Glumetzaxr.com. Full prescribing and safety information for CYCLOSET is available at www.Cycloset.com. Full prescribing and safety information for FENOGLIDE is available at www.Fenoglide.com. For Full prescribing and safety information for ZEGERID click here. |
- Phase I clinical trials: The product is tested in a small number of patients or healthy volunteers, primarily for safety at one or more doses.
- Phase II clinical trials: In addition to safety, the sponsor evaluates the efficacy of the products on targeted indications, and identifies possible adverse effects and safety risks, in a patient population somewhat larger than Phase I clinical trials.
- Phase III clinical trials: These trials typically involve additional clinical evaluations of safety and clinical efficacy in an expanded population at geographically-dispersed test sites.
- NDA (New Drug Application) or BLA (Biologics License Application) is submitted to FDA or foreign regulatory authority for review and approval.
- Marketed therapies are available in countries that have granted regulatory clearance.
For more detailed product information, please visit www.glumetzaxr.com
For more detailed product information, please visit www.cycloset.com
For more detailed product information, please visit www.fenoglide.com
